Given the investment horizon of 30 days, and your above average risk tolerance our recommendation regarding Cara Therapeutics is 'Strong Buy'. Macroaxis provides Cara Therapeutics buy hold or sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding CARA positions. The advice algorithm takes into account all of Cara Therapeutics available fundamental, technical, and predictive indicators you will find on this site. The advice is provided from CARA buy-and-hold prospective. Check also Cara Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for muliple equity instruments please use Instant Ratings tool.
For the selected time horizon Cara Therapeutics has a risk adjusted performance of 0.1475, jensen alpha of 0.7586, total risk alpha of (0.07), sortino ratio of 0.3154 and treynor ratio of 2.07Macroaxis buy, hold, or sell recommendation module can be used to complement current analysts and expert consensus on Cara Therapeutics. Our buy, hold, or sell suggestion engine makes use of analyzes the corporation potential to grow using all fundamental data market data available at the time. To make sure Cara Therapeutics is not overpriced, please confirm all Cara Therapeutics fundamentals including its Cash per Share, Short Ratio and the relationship between EBITDA and Current Ratio . Given that Cara Therapeutics has Price to Earning of (5.53)X, we suggest you validate Cara Therapeutics market performance and probability of bankruptcy to make sure the company can sustain itself in the current economic cycle given your prevailing risk tolerance and investing horizon.
Cara Therapeutics Trading Alerts and Improvement Suggestions
Cara Therapeutics appears to be very risky and stock price may revert if volatility continues
The company reported previous year revenue of 17.85M. Net Loss for the year was (79.21M) with loss before overhead, payroll, taxes, and interest of (62.06M).
Cara Therapeutics currently holds about 134.45M in cash with (31.36M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.38.
Roughly 62.0% of the company shares are held by institutions such as insurance companies
Cara Therapeutics currently demonstrates below average downside deviation of 2.12. It has Information Ratio of 0.17 and Jensen Alpha of 0.76. However, we do advice investors to further question Cara Therapeutics expected returns to make sure all indicators are consistent with the current outlook about its relatively low value at risk.